Opinions of Company Representatives About Neuromodulation

The goal of this online survey is to gain further insight in the goals, expectations and definition of success for neuromodulation for pain, according to neuromodulation company representatives.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuromodulation Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms Survey

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Vrije Universiteit Brussel

Jette, 1090, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain as company representatives will be eligible to complete the survey.

Exclusion criteria

Not a company representative.

Treatment and study plan

Filling in an online survey

Behavioral

Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.

Primary outcomes

Goals of company representatives, evaluated with a self-constructed question.

Time frame: Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.

Goals of company representatives to treat patients with neuromodulation for pain.
Company representatives expectations, evaluated with a self-constructed question.

Time frame: Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.

Factors that respondents expect to change according to neuromodulation for pain.
Company representatives definition of success of neuromodulation for pain, evaluated with a self-constructed question.

Time frame: Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.

Company representatives their definition of success of neuromodulation for pain.

Sponsors and collaborators

Lead sponsor

Moens Maarten

Other

Registry information

Official study title

Opinions of Company Representatives About Neuromodulation for Pain: an Online Survey

Important dates

Study start: 2021
Primary completion: 2021
Study completion: 2021
First posted: Aug 19, 2021
Registry last updated: Jan 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed